found that unaffected mucosa of UC patients showed no difference to healed mucosa of UC patients in remission and to mucosa of healthy controls. They concluded that the reason for a reduced protein production is very likely the inflammatory process per se.
Although not having received the same level of attention, efflux transporters now share their fate with the ␣ -defensins: a major role in the pathogenesis of IBD has been ruled out. In a recent publication in Gut , Lisa Simms [13] and her Australian colleagues had taken the ␣ -defensin story apart in a similar examination of a large series of more than 100 patients and controls with Crohn's disease or healthy guts. They showed that surface epithelial cells loss as a consequence of tissue damage by inflammation seems to be the main reason for the reduced protein expression of ␣ -defensins in patients with Crohn's disease. Gutmann and Simms have taught us that IBDs are more than an efflux transporter or defensin deficiency syndrome.
In their paper, Heike Gutmann [1] and her colleagues from Basel, Switzerland, nicely tell the story of the rise and fall of a suspected candidate in inflammatory bowel disease (IBD) pathogenesis by demonstrating that the efflux transporters BCRP (breast cancer resistance protein) and P-gp (P-glycoprotein) play no major role in the pathogenesis of ulcerative colitis (UC).
Among other organs important for uptake and elimination of toxic substances, the intestine expresses BCRP and P-gp in the apical membrane of the enterocytes [2-6] . Previous genetic studies have reported that the P-gp and BCRP production is down-regulated in patients with active UC [7] [8] [9] [10] and data indicated that their genetic locus is associated with a susceptibility for UC [11, 12] . However, previous studies did not differentiate between the transporter expression in inflamed or unaffected mucosa and did not take into account whether the UC patients took anti-inflammatory medication. Therefore, Gutmann et al.
[1] evaluated transporter expression in both unaffected and inflamed mucosa of patients with active UC, in drug-naive and treated patients with UC and compared the results to transporter expression in healthy subjects. They confirmed that P-gp and BCRP production is significantly reduced in the inflamed mucosa of treated and untreated patients with active UC, but they 
